NasdaqCM - Delayed Quote • USD
Galmed Pharmaceuticals Ltd. (GLMD)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 6:09 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -1.29 | -1.03 |
| Low Estimate | 0 | 0 | -1.29 | -1.03 |
| High Estimate | 0 | 0 | -1.29 | -1.03 |
| Year Ago EPS | -1.09 | -0.95 | -2.5 | -1.29 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.5 | -0.34 | -0.27 | -0.32 |
| EPS Actual | -1.09 | -0.95 | -0.24 | -0.98 |
| Difference | 0.41 | -0.61 | 0.03 | -0.66 |
| Surprise % | 27.30% | -179.40% | 11.10% | -206.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -1.29 | -1.03 |
| 7 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 30 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 60 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 90 Days Ago | 0 | 0 | -1.29 | -1.03 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GLMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 9.10% |
| Next Qtr. | -- | -- | -- | 11.50% |
| Current Year | 48.40% | -- | -- | 5.70% |
| Next Year | 20.20% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 20.00% | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Maxim Group: Hold to Buy | 7/24/2023 |
| Downgrade | Maxim Group: Buy to Hold | 8/8/2022 |
| Downgrade | Canaccord Genuity: Buy to Hold | 8/8/2022 |
| Downgrade | Raymond James: Outperform to Market Perform | 5/18/2022 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/3/2022 |
| Maintains | Raymond James: Outperform | 5/3/2022 |
Related Tickers
GALT Galectin Therapeutics Inc.
2.6000
-1.89%
BLPH Bellerophon Therapeutics, Inc.
0.0575
0.00%
MRZM Marizyme, Inc.
0.0533
0.00%
RNXT RenovoRx, Inc.
1.0200
-1.92%
TCON TRACON Pharmaceuticals, Inc.
1.1400
-3.39%
THAR Tharimmune, Inc.
5.20
+1.17%
CKPT Checkpoint Therapeutics, Inc.
1.8900
0.00%
INM InMed Pharmaceuticals Inc.
0.2354
-7.69%
ENTX Entera Bio Ltd.
2.0000
-4.31%
ARTL Artelo Biosciences, Inc.
1.3982
+0.59%